CHI: Immunogenicity & Bioassay Summit

October 2 – 5, 2023
The Watergate Hotel
Washington, D.C. 
BOOTH: #10

We look forward to meeting you in Washington, D.C.

Request a meeting with our team to learn how we help our clients advance their drug modality.

Schedule a Meeting

Speak with our scientific experts onsite to discuss your project.

I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.



Don’t miss our presentations at this year's Summit:

Immunogenicity of Cell and Gene Therapies
Cellular Immunogenicity Assessment for Advanced Modalities
Jim McNally, PhD, Chief Scientific Officer, BioAgilytix
Tuesday, Oct 3rd
10:50- 11:20 a.m.

Panel Discussion
Advances in Cell and Gene Therapy Drug Development and the Impact on Cellular Immunogenicity
Boris Gorovits, PhD, Vice President, Bioanalytical & Non-Clinical Biomarkers, Sana Biotechnology
Anurag Sharma, PhD, Gene Therapy Reviewer, CBER, FDA
Jim McNally, PhD, CSO, BioAgilytix
Sally Ye, Scientist, DMPK, Boehringer Ingelheim

Short courses
SC1: Development of Neutralizing Antibody Assays, Technical Considerations and Case Studies
Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix
Jim McNally, PhD, CSO, BioAgilytix
Monday, Oct. 2nd
9:00 – 12:00 p.m.

SC2: Overcoming Drug and Target Interference in ADA and NAb Assays
Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix
Weifeng Xu, PhD, Director, Bioanalytical, Merck
Monday, Oct. 2nd
2:00 – 5:00 p.m.

SC4: Recent Advances with Cell and Gene Therapy - IN-PERSON ONLY
Jim McNally, PhD, Chief Scientific Officer, BioAgilytix
Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix
Monday, Oct. 2th
5:30 – 8:30 p.m.


Track: Optimizing Bioassays for Biologics
Development and Optimization of Potency Assays for ATMPs and Utilization of the Matrix Approach
Jessica Weaver, Associate Director, CMC Bioanalytical Operations
Wednesday, Oct 4th
2:00- 2:30 p.m.

About the event

CHI is excited to host its 15th Annual Immunogenicity & Bioassay Summit – a hybrid event. We’ll examine challenges facing the industry with NEW case studies, NEW perspectives, and NEW approaches.


Schedule a meeting with our experts onsite

Speak with our team about how the combination of world-class scientific expertise, outstanding project management, and superior regulatory insight can expedite your advanced therapeutic. You can also fill out the form, and an expert will reach out to schedule a meeting with you onsite.

Durham Lab (USA HQ)
2300 Englert Drive
Durham, NC 27713

Hamburg Lab (EU HQ)
Ladenmannbogen 10
22339 Hamburg Germany
+49 40 526779 0

Boston Lab
1320 Soldiers Field Road
Boston, MA 02135

San Diego Lab
9050 Camino Santa Fe
San Diego, CA 92121

Brisbane Lab
37 Kent St, Woolloongabba
Queensland, 4102, Australia

Melbourne Lab
85 Commercial Road, Melbourne
Victoria, 3004, Australia

Copyright © 2023 BioAgilytix Labs